Hepatitis C Virus Infection And Metabolic Syndrome—A Community-Based Study in an Endemic Area of Taiwan

Hepatitis C Virus Infection And Metabolic Syndrome—A Community-Based Study in an Endemic Area of Taiwan

Metabolic syndrome (MS) is a complicated disorder associated with a high risk of future development of micro- and macrovascular complications. The extrahepatic manifestations of hepatitis C virus (HCV) infection can include multiple metabolic abnormalities. However, the extent, severity, and charact...

Full description

Bibliographic Details
Main Authors:	Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu, Sung-Hua Yu, Chung-Feng Huang, Ching-I Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Jeng-Fu Yang, Zu-Yau Lin, Shinn-Chern Chen, Chia-Yen Dai, Wen-Yu Chang
Format:	Article
Language:	English
Published:	Wiley 2009-06-01
Series:	Kaohsiung Journal of Medical Sciences
Subjects:	hepatitis C virus insulin resistance metabolic syndrome
Online Access:	http://www.sciencedirect.com/science/article/pii/S1607551X09705200

Similar Items

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study
by: Ming-Lun Yeh, et al.
Published: (2016-11-01)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
by: Ying-Chou Huang, et al.
Published: (2021-01-01)

Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan
by: Pei‐Chien Tsai, et al.
Published: (2022-07-01)

Association between gallbladder stones and chronic hepatitis C: Ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan
by: Chia-Yen Dai, et al.
Published: (2013-08-01)

Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma
by: Ming-Lun Yeh, et al.
Published: (2015-02-01)

Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection
by: Chung-Feng Huang, et al.
Published: (2015-05-01)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma.
by: Ming-Lun Yeh, et al.
Published: (2017-01-01)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients.
by: Jee-Fu Huang, et al.
Published: (2015-01-01)

Glucose abnormalities in hepatitis C virus infection
by: Jee-Fu Huang, et al.
Published: (2013-02-01)

Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis
by: Jee-Fu Huang, et al.
Published: (2020-01-01)

Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma
by: Zu‐Yau Lin, et al.
Published: (2021-07-01)

Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression
by: Zu‐Yau Lin, et al.
Published: (2022-02-01)

Association of hyperuricemia with disease severity in chronic hepatitis C patients.
by: Tyng-Yuan Jang, et al.
Published: (2018-01-01)

Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study
by: Jeng-Fu Yang, et al.
Published: (2010-09-01)

Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy
by: Ming‐Lun Yeh, et al.
Published: (2021-02-01)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
by: Chung-Feng Huang, et al.
Published: (2021-01-01)

Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan
by: Meng-Hsuan Hsieh, et al.
Published: (2016-02-01)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients
by: Ching-I Huang, et al.
Published: (2017-08-01)

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2019-01-01)

Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan
by: Meng-Hsuan Hsieh, et al.
Published: (2016-10-01)

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment
by: Ming‐Lun Yeh, et al.
Published: (2019-10-01)

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
by: Ming-Lung Yu, et al.
Published: (2018-06-01)

The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases
by: Yi-Hung Lin, et al.
Published: (2016-07-01)

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2015-01-01)

Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients.
by: Jee-Fu Huang, et al.
Published: (2017-01-01)

Interactive effects between Lymphotoxin α +252 polymorphism and habits of substance use on risk of hepatocellular carcinoma
by: Jung-Fa Tsai, et al.
Published: (2017-07-01)

Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.
by: Chung-Feng Huang, et al.
Published: (2013-01-01)

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection
by: Ta-Ya Lin, et al.
Published: (2017-06-01)

Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
by: Tzu‐Sheng Cheng, et al.
Published: (2021-04-01)

Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules
by: Zu‐Yau Lin, et al.
Published: (2020-06-01)

Performance characteristics of a combined hepatitis C virus core antigen and anti–hepatitis C virus antibody test in different patient groups
by: Jeng-Fu Yang, et al.
Published: (2011-07-01)

Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
by: Meng-Hsuan Hsieh, et al.
Published: (2018-06-01)

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
by: Tsai Jung-Fa, et al.
Published: (2005-04-01)

Comparison of Clinical Application of the Abbott HBV PCR Kit and the Versant HBV DNA 3.0 Test to Measure Serum Hepatitis B Virus DNA in Taiwanese Patients
by: Jeng-Fu Yang, et al.
Published: (2009-08-01)

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
by: Ming-Ying Lu, et al.
Published: (2021-04-01)

Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
by: Zu-Yau Lin, et al.
Published: (2023-10-01)

Unawareness of hepatitis B infection and lack of surveillance are associated with severity of hepatocellular carcinoma
by: Kuan‐I Lee, et al.
Published: (2023-11-01)

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
by: Yi-Shan Tsai, et al.
Published: (2022-04-01)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
by: Yi-Shan Tsai, et al.
Published: (2020-07-01)

Abbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapy.
by: Ming-Lun Yeh, et al.
Published: (2014-01-01)